Good morning, everyone, and welcome to Moderna's Second Digital Investor Event. Since our first digital event in early 2020, we have made great progress in our digital strategy and the role of AI in ...

Good day, and thank you for standing by. Welcome to the Moderna Fourth Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there ...

Stéphane Bancel: Thank you, Lavina. Good morning or good afternoon, everyone. Thank you for joining us today. I will start with a review of our business in Q1. Jamey will present our financial results ...

Messenger RNA (mRNA) technology came of age during COVID-19 with several vaccines and therapeutics coming to market. However, since the height of the pandemic, the flow of new mRNA-based products has ...

How does the cell convert DNA into working proteins? The process of translation can be seen as the decoding of instructions for making proteins, involving mRNA in transcription as well as tRNA. But ...

The discovery of chemical modifications to overcome mRNA’s instability and immunotoxicity have enabled mRNA therapeutics to evolve dramatically, reaching clinical trials and the forefront of modern ...

A new study at Hebrew University reveals insights into mRNA regulation during embryonic development. The study combines single-cell RNA-Seq and metabolic labeling in zebrafish embryos, distinguishing ...

Stéphane Bancel: Thank you, Lavina. Good morning or good afternoon, everyone. Thank you for joining us. I will start with a review of 2024. Jamey will present our financial results and outlook.

Revenue-- $1.9 billion reported for the quarter, compared to prior sales cycles impacted by earlier U.S. COVID-19 vaccine approval. Net Income-- $13 million, up from a loss of $3.6 billion in the same ...